Market Overview:
The global vesicular stomatitis (VS) therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of VS, rising demand for effective and affordable therapeutics, and growing awareness about VS among veterinarians and pet owners. The global vesicular stomatitis (VS) therapeutics market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into symptomatic medications and vaccination. Symptomatic medications are further sub-segmented into antiviral agents, analgesics/pain relief drugs, anti-inflammatory drugs, and other symptomatic medications. Vaccination is further sub-segmented into inactivated vaccine and live attenuated vaccine. On the basis of application, the market is segmented into veterinary hospitals, veterinary clinics,,and retail pharmacies.On the basis of region,.Latin America,.Europe,.Asia Pacific.,and Middle East & Africa.
 Therapeutics Industry Outlook.svg)
Product Definition:
A virus that causes sores in the mouth, and sometimes on the hooves and teats of cattle, horses, pigs, and other animals. It can also infect people. There is no cure for vesicular stomatitis, but antiviral drugs may help lessen symptoms.
Symptomatic Medications:
Vesicular stomatitis is a rare disorder affecting the gastrointestinal tract. It is an autosomal recessive genetic disorder with an incidence of 1 per 100,000 individuals. The disease has a high prevalence in Japan (1:10,000) and India (1:20,000).
Vaccination:
Vaccination is the procedure of introducing an attenuated ( weakened) form of a disease-causing agent into the body to stimulate the immune system and create antibodies. The most common diseases for which vaccination is used are measles, polio, chickenpox, mumps, and rubella.
The VS therapeutics market has witnessed tremendous growth in recent years due to rising incidences of this life-threatening disorder.
Application Insights:
The use of vesicular stomatitis in veterinary hospitals accounted for the largest revenue share in 2017. The rising prevalence of animal diseases, coupled with a growing number of pet animals worldwide, is anticipated to contribute towards the segment growth over the forecast period.
VS can be effectively treated by medication and surgery; however, due to lack of awareness among farmers and veterinarians about VS infection transmission route and treatment method, many farmers still prefer vaccination as an alternative approach for controlling this disease. This has resulted in low usage rate of surgical procedures compared to medication for its treatment.
In terms of revenue generation capacity, veterinary clinics are expected register significant growth at a CAGR around 11% from 2018 to 2030 owing to factors such as increasing adoption rate companion animals across households globally along with high demand services offered by these clinics worldwide.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and suppliers, availability of advanced products, high awareness levels coupled with relatively higher healthcare expenditure levels are some factors attributing to its largest share. In addition, increasing incidence rate is one more factor that can be attributed to its largest share. According to the North American Pet Health Insurance Association (NAPHIA), over 2 million pets were insured in U.S.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising disposable income leading towards an increase in pet adoption rates which will eventually drive demand for veterinary medicines and vaccines used for treating this condition thus fueling regional market growth during the forecast period.
Growth Factors:
- Increasing incidence of VS in livestock: The global incidence of VS is increasing due to the increase in international trade and travel. The disease is now being reported from more than 60 countries.
- Emergence of new VS viruses: In the past, only two serotypes (New Jersey and Indiana) of Vesicular Stomatitis virus (VSV) were known to cause disease in livestock but recently, a number of new serotypes have been identified including Colorado and Texas serotypes. This has increased the complexity of diagnosis and treatment.
- Development of novel therapeutics: There is a need for better therapeutics for treating VS infections in both animals and humans. Novel therapies are currently being developed that may prove to be more effective than the current treatments available.
Scope Of The Report
Report Attributes
Report Details
Report Title
Vesicular Stomatitis (VS) Therapeutics Market Research Report
By Type
Symptomatic Medications, Vaccination
By Application
Veterinary Hospitals, Veterinary Clinics, Retail Pharmacies
By Companies
Boehringer Ingelheim, Merck & Co, Zoetis, Vedco, Elanco, Ceva Santé Animale, Vibrac, Vetoquinol, IDEXX Laboratories, Covetrus, Neogen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Vesicular Stomatitis (VS) Therapeutics Market Report Segments:
The global Vesicular Stomatitis (VS) Therapeutics market is segmented on the basis of:
Types
Symptomatic Medications, Vaccination
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Veterinary Hospitals, Veterinary Clinics, Retail Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Boehringer Ingelheim
- Merck & Co
- Zoetis
- Vedco
- Elanco
- Ceva Santé Animale
- Vibrac
- Vetoquinol
- IDEXX Laboratories
- Covetrus
- Neogen
 Therapeutics Market Overview.svg)
Highlights of The Vesicular Stomatitis (VS) Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Symptomatic Medications
- Vaccination
- By Application:
- Veterinary Hospitals
- Veterinary Clinics
- Retail Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Vesicular Stomatitis (VS) Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Therapeutics Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
VS Therapeutics is a biotechnology company focused on the development of novel therapeutics for vesicular stomatitis (VS). VS is a viral disease that causes inflammation and ulceration in the mouth. The Company's lead product candidate, VX-809, is an investigational oral treatment for VS that targets the virus' replication cycle.
Some of the major players in the vesicular stomatitis (vs) therapeutics market are Boehringer Ingelheim, Merck & Co, Zoetis, Vedco, Elanco, Ceva SantƒÂ© Animale, Vibrac, Vetoquinol, IDEXX Laboratories, Covetrus, Neogen.
The vesicular stomatitis (vs) therapeutics market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Vesicular Stomatitis (VS) Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Vesicular Stomatitis (VS) Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Vesicular Stomatitis (VS) Therapeutics Market - Supply Chain
4.5. Global Vesicular Stomatitis (VS) Therapeutics Market Forecast
4.5.1. Vesicular Stomatitis (VS) Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Vesicular Stomatitis (VS) Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Vesicular Stomatitis (VS) Therapeutics Market Absolute $ Opportunity
5. Global Vesicular Stomatitis (VS) Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Type
5.3.1. Symptomatic Medications
5.3.2. Vaccination
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Vesicular Stomatitis (VS) Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Application
6.3.1. Veterinary Hospitals
6.3.2. Veterinary Clinics
6.3.3. Retail Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Vesicular Stomatitis (VS) Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Vesicular Stomatitis (VS) Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Vesicular Stomatitis (VS) Therapeutics Demand Share Forecast, 2019-2026
9. North America Vesicular Stomatitis (VS) Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Application
9.4.1. Veterinary Hospitals
9.4.2. Veterinary Clinics
9.4.3. Retail Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Type
9.7.1. Symptomatic Medications
9.7.2. Vaccination
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Vesicular Stomatitis (VS) Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Vesicular Stomatitis (VS) Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Application
10.4.1. Veterinary Hospitals
10.4.2. Veterinary Clinics
10.4.3. Retail Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Type
10.7.1. Symptomatic Medications
10.7.2. Vaccination
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Vesicular Stomatitis (VS) Therapeutics Demand Share Forecast, 2019-2026
11. Europe Vesicular Stomatitis (VS) Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Application
11.4.1. Veterinary Hospitals
11.4.2. Veterinary Clinics
11.4.3. Retail Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecst by Type
11.7.1. Symptomatic Medications
11.7.2. Vaccination
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Vesicular Stomatitis (VS) Therapeutics Demand Share, 2019-2026
12. Asia Pacific Vesicular Stomatitis (VS) Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Application
12.4.1. Veterinary Hospitals
12.4.2. Veterinary Clinics
12.4.3. Retail Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Type
12.7.1. Symptomatic Medications
12.7.2. Vaccination
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Vesicular Stomatitis (VS) Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Vesicular Stomatitis (VS) Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Application
13.4.1. Veterinary Hospitals
13.4.2. Veterinary Clinics
13.4.3. Retail Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Vesicular Stomatitis (VS) Therapeutics Market Size and Volume Forecast by Type
13.7.1. Symptomatic Medications
13.7.2. Vaccination
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Vesicular Stomatitis (VS) Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Vesicular Stomatitis (VS) Therapeutics Market: Market Share Analysis
14.2. Vesicular Stomatitis (VS) Therapeutics Distributors and Customers
14.3. Vesicular Stomatitis (VS) Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Boehringer Ingelheim
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck & Co
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Zoetis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Vedco
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Elanco
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Ceva Santé Animale
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Vibrac
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Vetoquinol
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. IDEXX Laboratories
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Covetrus
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Neogen
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
